Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis

Cytokine and Growth Factor Reviews

Volumn 7, Issue 2, 1996, Pages 175-190

  Beauparlant, Pierre ^b   Hiscott, John ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cytokine synthesis; Inhibitors; NF B Rel proteins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; I-REL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; ONCOGENE PROTEIN REL; ONCOPROTEIN; PROSTAGLANDIN E2; PROTEINASE INHIBITOR; TSUKUBAENOLIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; ANIMAL CELL; BIOSYNTHESIS; DRUG EFFECT; ENZYME INHIBITION; FORECASTING; GENETIC TRANSCRIPTION; GENETICS; GROWTH REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; METABOLISM; MUTATION; NONHUMAN; PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0030207078     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00020-2     Document Type: Short Survey

References (141)

1. 1. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of HIV-1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors. Microbiol Rev 1995, 59, 481-505.
2. 2. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995, 80, 529-532.
3. 3. Verma IM, Stevenson JK, Schwarz EM, Antwerp DV, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Devl 1995, 9, 2723-2735.
4. 4. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Ann Rev Immunol 1994, 12, 141-179.
5. 5. Ghosh G, Van Duyne G, Ghosh S, Sigler PB. Structure of NF-κB p50 homodimer bound to a κB site. Nature 1995, 373, 303-310.
6. 6. Müller CW, Rey FA, Sodeoka M, Verdine GL, Harrison SC. Structure of the NF-κB p50 homodimer bound to DNA. Nature 1995, 373, 311-350.
7. 7. Henkel T, Zabel U, van Zee K, Müller JM, Fanning E, Baeuerle PA. Intramolecular masking of the nuclear location signal and dimerization domain in the precursor for the p50 NF-κB subunit. Cell 1992, 68, 1121-1133.
8. 8. Fan C-M, Maniatis T. Generation of p50 subunit of NF-κB by processing of p105 through an ATP-dependant pathway. Nature 1991, 354, 395-398.
9. 9. Palombella VL, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteosome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994, 78, 773-785.
10. 10. Inoue JI, Kerr LD, Ransone LJ, Bengal E, Hunter T, Verma IM. c-rel activates but v-rel suppresses transcription from κB sites. Proc Natl Acad Sci USA 1991, 88, 3715-3719.
11. 11. Bull P, Morley KL, Hoekstra MF, Hunter T, Verma IM. The mouse c-Rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Molec Cell Biol 1990, 10, 5473-5485.
12. 12. Perkins ND, Schmid RM, Duckett, CS, Leung K, Rice NR, Nabel GJ. Distinct combinations of NF-κB subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA 1992, 89, 1529-1533.
13. 13. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J 1991, 10, 3805-3817.
14. 14. Ruben SM, Klement JF, Coleman TA, Maher M, Chen C-H, Rosen CA. I-rel: a novel rel-related protein that inhibits NF-κB transcriptional activity. Genes Devl 1992, 6, 745-760.
15. 15. Kunsch C, Ruben SM, Rosen CA. Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Molec Cell Biol 1992, 12, 4412-4421.
16. 16. Lin R, Gewert D, Hiscott J. Differential transcriptional activation in vitro by NF-κB/Rel proteins. J Biol Chem 1995, 270, 3123-3131.
17. 17. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 1995, 376, 167-170.
18. 18. Sha WC, Liou HC, Tuomanen El, Baltimore D. Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995, 80, 321-330.
19. 19. Bitar R, Beauparlant P, Lin R, Pitha P, Hiscott J. Retrovirus-mediated transfer of nuclear factor-κB subunit genes modulates IκBα and interferon β expression. Cell Growth Differ 1995, 6, 965-976.
20. 20. Köntgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S. Mice lacking the c-rel protooncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Devl 1995, 9, 1965-1977.
21. 21. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck R-P, Lira SA, Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 1995, 80, 331-340.
22. 22. Burly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D. Expression of RelB is required for the development of thymic medulla and dendritic cells. Nature 1995, 373, 531-536.
23. 23. Beg AA, Baldwin S Jr. The IκB proteins: multifunctional regulators of Rel/NF-κB transcription factors. Genes Devl 1993, 7, 2064-2070.
24. 24. Rosette C, Karin M. Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-κB. J Cell Biochem 1995, 128, 1111-1119.
25. 25. Haskill S, Beg AA, Tompkins SM, Morris JS, Yurochko AD, Sampson-Johannes A, Mondal K, Ralph P, Baldwin AS Jr. Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity. Cell 1991, 65, 1281-1289.
26. 26. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 1995, 80, 573-582.
27. 27. Inoue JI, Kerr LD, Kakizuka A, Verma I. IκBγ, a 70 kd protein identical to the c-terminal half of p110 NF-κB: a new member of the IκB family. Cell 1992, 68, 1109-1120.
28. 28. Liou H-C, Nolan GP, Ghosh S, Fujita T, Baltimore D. The NF-κB p50 precursor, p105, contains an internal IκB-like inhibitor that preferentially inhibits p50. EMBO J 1992, 11, 3003-3009.
29. 29. Hatada EN, Nieters A, Wulczyn FG, Naumann M, Meyer R, Nucifora G, McKeithan TW, Scheidereit C. The ankyrin repeat domains of the NF-κB precursor p105 and the proto-oncogene bcl-3 act as specific inhibitors of NF-κB DNA binding. Proc Natl Acad Sci USA 1992, 89, 2489-2493.
30. 30. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature 1992, 359, 339-342.
31. 31. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell-cycle control. Cell 1990, 60, 991-997.
32. 32. Rice NR, MacKichan ML, Israel A. The precursor of NF-κB p50 has IκB-like functions. Cell 1992, 71, 243-253.
33. 33. Rice NR, Ernst MK. In vivo control of NF-κB activation by Iκ-Bα. EMBO J 1993, 12, 4685-4695.
34. 34. Scott ML, Fujita T, Liou H-C, Nolan GP, Baltimore D. The p65 subunit of NF-κB regulates IκB by two distinct mechanisms. Genes Devl 1993, 7, 1266-1276.
35. 35. Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-κB controls expression of inhibitor IκBα: evidence for an inducible autoregulatory pathway. Science 1993, 259, 1912-1915.
36. 36. McElhinny JA, Trushin SA, Bren GD, Chester N, Paya CV. Casein kinase II phosphorylates IκBα at S-283, S-289, S-293, and T-291 and is required for its degradation. Molec Cell Biol 1996, 16, 899-906.
37. 37. Barroga CF, Stevenson JK, Schwarz EM, Verma IM. Constitutive phosphorylation of IκBα by casein kinase II. Proc Natl Acad Sci USA 1995, 92, 7637-7641.
38. 38. Lin R, Beauparlant P, Makris C, Meloche S, Hiscott J. Phosphorylation of IκBα in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. Molec Cell Biol 1996, 16, 1401-1409.
39. 39. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IκBα: a mechanism for NF-κB activation. Molec Cell Biol 1993, 13, 3301-3310.
40. 40. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκBα. Proc Natl Acad Sci USA 1993, 90, 2532-2536.
41. 41. Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y. In vivo stimulation of IκB phosphorylation is not sufficient to activate NF-κB. Molec Cell Biol 1995, 15, 1294-1301.
42. 42. Finco TS, Beg AA, Baldwin AS Jr. Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors. Proc Natl Acad Sci USA 1994, 91, 11884-11888.
43. 43. Lin Y-C, Brown K, Siebenlist U. Activation of NF-κB requires proteolysis of the inhibitor IκBα: signal-induced phosphorylation of IκB-α alone does not release active NF-κB. Proc Natl Acad Sci USA 1995, 92, 552-556.
44. 44. Traenckner EB-M, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of IκB-α that is still bound to NF-κB. EMBO J 1994, 13, 5433-5441.
45. 45. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, Maniatis T. Signal-induced site-specific phosphorylation targets IκBα to the ubiquitin-proteasome pathway. Genes Devl 1995, 9, 1586-1597.
46. 46. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1995, 92, 10599-10603.
47. 47. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BRG. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc Natl Acad Sci USA 1994, 91, 6288-6292.
48. 48. Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence P, Silverman RH. Blockage of NF-κB signalling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994, 265, 789-792.
49. 49. Diaz-Meco MT, Dominguez I, Sanz L, Dent P, Lozano J, Municio MM, Berra E, Hay RT, Sturgill TW, Moscat J. ζ PKC induces phosphorylation and inactivation of IκBα in vitro. EMBO J 1994, 13, 2842-2848.
50. 50. Lint JV, Agostinis P, Vandevoorde V, Haegeman G, Fiers W, Merlevede W, Vadenheede JR. Tumor necrosis factor stimulates multiple serine/threonine protein kinases in Swiss 3T3 and L929 cells. J Biol Chem 1992, 267, 25916-25921.
51. 51. Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-jun kinase. J Biol Chem 1995, 269, 26396-26401.
52. 52. Diaz-Meco MT, Berra E, Municio MM, Sanz L, Dominquez I, Diaz-Golpe V, Lain de Lera MT, Alcami J, Paya CV, et al. A dominant negative protein kinase C ζ subspecies blocks NF-κB activation. Molec Cell Biol 1993, 13, 4770-4775.
53. 53. Finco TS, Baldwin AS Jr. κB site-dependent induction of gene expression by diverse inducers of nuclear factor κB requires Raf-1. J Biol Chem 1993, 268, 17676-17679.
54. 54. Li S, Sedivy JM. Raf-1 protein kinase activates the NF-κB transcription factor by dissociating the cytoplasmic NF-κB-IκB complex. Proc Natl Acad Sci USA 1993, 90, 9247-9251.
55. 55. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 1995, 267, 1485-1488.
56. 56. Whiteside ST, Ernst MK, LeBail O, Laurent-Winter C, Rice N, Israel A. N- and C-terminal sequences control degradation of MAD3/IκBα in response to inducers of NF-κB activity. Molec Cell Biol 1995, 15, 5339-5345.
57. 57. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in IκBα to multiple pathway for NF-κB activation. Molec Cell Biol 1995, 15, 2809-2818.
58. 58. Beg AA, Sha WC, Bronson RT, Baltimore D. Constitutive NF-κB activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes Devl 1995, 9, 2736-2746.
59. 59. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Baldwin AS Jr. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Devl 1992, 6, 1899-1913.
60. 60. Arenzana-Seisdedos F, Thompson J, Rodriguez MS, Bachelerie F, Thomas D, Hay RT. Inducible nuclear expression of newly synthesized IκBα negatively regulates DNA-binding and the transcriptional activities of NF-κB. Molec Cell Biol 1995, 15, 2689-2696.
61. 61. Scherer DC, Brockman JA, Chen Z, Maniatis T, Ballard DW. Signal-induced degradation of IκBα requires site-specific ibiquitination. Proc Natl Acad Sci USA 1995, 92, 11259-11263.
62. 62. Sun S-C, Elwood J, Greene WC. Both amino- and carboxyl-terminal sequences within IκBα regulate its inducible degradation. Molec Cell Biol 1996, 16, 1058-1065.
63. 63. Baldi L, Brown K, Franzoso G, Siebenlest U. Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of IκBα. J Biol Chem 1996, 271, 376-379.
64. 64. Muroi M, Muroi Y, Ito N, Rice NR, Suzuki T. Effects protease inhibitors on LPS-mediated activation of a mouse macrophage cell line (J774). J Endocr Res 1995, 2, 337-347.
65. 65. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of IκBα activity. Proc Natl Acad Sci USA 1994, 91, 28-32.
66. 66. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature 1993, 365, 182-185.
67. 67. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994, 79, 13-21
68. 68. DiDonato JA, Mercurio F, Karin M. Phosphorylation of IκBα precedes but is not sufficient for its dissociation from NF-κB. Molec Cell Biol 1995, 15, 1302-1311.
69. 69. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM. Tumor necrosis factor α-induced phosphorylation of IκBα is a signal for its degradation but not dissociation from NF-κB. Proc Natl Acad Sci USA. 1994, 91, 12740-12744.
70. 70. Figueiredo-Pereira ME, Banik N, Wilk S. Comparison of the effect of calpain inhibitors on two extralysosomal proteinases: The multicatalytic protinease complex and m-calpain. J Neurochem 1994, 62, 1989-1994.
71. 71. Wilk S, Figueiredo-Pereira ME. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enz Prot 1993, 47, 306-313.
72. 72. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78, 761-771.
73. 73. Sun SC, Maggirwar SB, Harhaj E. Activation of NF-κB by phosphatase inhibitors involves the phosphorylation of IκBα at phosphatase 2A-sensitive sites. J Biol Chem 1995, 270, 18347-18351.
74. 74. Maggirwar SB, Harhaj E, Sun SC. Activation of NF-κB/Rel by Tax involves degradation of IκBα and is blocked by a proteasome inhibitor. Oncogene 1995, 11, 993-998.
75. 75. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995, 2, 493-506.
76. 76. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Int Med 1993, 119, 1198-11208.
77. 77. Yang J, Defranco DB. Assessment of glucocorticoid receptor heat shock protein 90 interactions in vivo during nucleocytoplasmic trafficking. Molec Endocr 1996, 10, 3-13.
78. 78. Hutchison KA, Scherrer LC, Czar MJ, Stancato LF, Chow YH, Jove R, Pratt WB. Regulation of glucocorticoid receptor function through assembly of a receptor-heat shock protein complex. Ann NY Acad Sci 1993, 684, 35-48.
79. 79. Beato M, Herrlich P, Günther S. Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83, 851-857.
80. 80. Meylan PRA, Guatelli JC, Munis JR, Richman DD, Kornbluth RS. Mechanisms for the inhibition of HIV replication by interferons-α, -β, and -γ in primary human macrophages. Virology 1993, 193, 138-148.
81. 81. Naumann M, Wulczyn FG, Scheidereit C. The NF-κB precursor p105 and the proto-oncogene product Bcl-3 are IκB molecules and control nuclear translocation of NF-κB. EMBO J 1993, 12, 213-222.
82. 82. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995, 270, 283-286.
83. 83. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-κB activity through induction of IκB synthesis. Science 1995, 270, 286-290.
84. 84. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, Van der Saag PT. Negative cross-talk between RelA and the glucocorticoid receptor; a possible mechanism for the antiinflammatory action of glucocorticoids. Molec Endocr 1995, 9, 401-412.
85. 85. Batuman OA, Ferrero AP, Diaz A, Berger B, Pomerantz R. Glucocorticoid-mediated inhibition of interleukin-2 receptor α and -β subunit expression by human T cells. Immunopharmacology 1994, 27, 43-55.
86. 86. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Molec Cell Biol 1995, 15, 943-953.
87. 87. Ray A, Prefontaine KE, Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994, 91, 752-756.
88. 88. Ghooi RB, Thatte SM, Joshi PS. The mechanism of action of aspirin - is there anything beyond cyclo-oxygenase? Med Hypo 1995, 44, 77-80.
89. 89. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994, 265, 956-959.
90. 90. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-κB. Science 1995, 270, 2017-2018.
91. 91. Jabbar SA, Hoffbrand AV, Wickremasinghe RG. Redox reagents and staurosporin inhibit stimulation of the transcription regulator NF-κB following tumor necrosis factor treatment of chronic B-leukaemia cells. Leuk Res 1994, 18, 523-530.
92. 92. Uotila P. Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immunol Immunother 1993, 37, 251-254.
93. 93. Kammer GH. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 1988, 9, 222-229.
94. 94. Neumann M, Grieshammer T, Chuvpilo S, Kneitz B, Lohoff M, Schimpl A, Franza BR Jr, Serfling E. RelA/p65 is a molecular target for the immunosuppressive action of the protein kinase A. EMBO J 1995, 14, 1991-2004.
95. 95. Chen D, Rothenberg EV. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcriptional role. J Exp Med 1994, 179, 931-942.
96. 96. Watanabe S, Yssel H, Harada Y, Arai K. Effects of prostaglandin E2 on Th0-type human T cell clones: modulation of functions of nuclear proteins involved in cytokine production. Int Immunol 1994, 6, 523-532.
97. 97. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994, 26, 3272-3275.
98. 98. Rao A. NFATp, a cyclosporin-sensitive transcription factor implicated in cytokine gene induction. J Leukocyte Biol. 1995, 57, 536-542.
99. 99. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989, 246, 1617-1620.
100. 100. Pimentel-Muinos FX, Mazana J, Fresno M. Biphasic control of nuclear factor-κB activation by the T cell receptor complex: role of tumor necrosis factor α. Eur J Immunol 1995, 25, 179-186.
101. 101. McCaffrey PG, Kim PK, Valge-Archer VE, Sen R, Rao A. Cyclosporin A sensitivity of the NF-κB site of the IL2Rα promoter in untransformed murine T cells. Nucl Acids Res 1994, 22, 2134-2142.
102. 102. Okamoto S, Mukaida N, Yasumoto K, Rice N, Ishikawa Y, Horiguchi H, Murakami S, Matsushima K. The interleukin-8 AP-1 and κB-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. J Biol Chem 1994, 269, 8582-8589.
103. 103. Kunz D, Walker G, Eberhardt W, Nitsch D, Pfeilschifter J. Interleukin 1-β-induced expression of nitric oxide synthase in rat renal mesanglial cells is suppressed by cyclosporin A. Biochim Biophys Res Commun 1995, 216, 438-446.
104. 104. Cockerill GW, Bert AG, Ryan GR, Gamble JR, Vadas MA, Cockerill PN. Regulation of granulocyte-macrophage-colony stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and T-cell transcription factor NFAT. Blood 1995, 86, 2689-2698.
105. 105. Lai JH, Tan YH. CD28 signaling causes a sustained down-regulation of IκBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994, 269, 30077-30080.
106. 106. Wechsler AS, Gordon MC, Dendorfer U, LeClair KP. Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994, 153, 2515-2523.
107. 107. Mattila PS, Ullman KS, Fiering S, Emmel EA, McCutcheon M, Crabtree GR, Herzenberg LA. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J 1990, 9, 4425-4433.
108. 108. Su MS, Semerjian A. Activation of transcription factor NF-κB in Jurkat cells is inhibited selectively by FK506 in a signal-dependent manner. Transplant Proc 1991, 23, 2912-2915.
109. 109. Franz B, Nordby EC, Bren G, Steffan N, Paya CV, Kincaid RL, Tocci MJ, O'Keefe SJ, O'Neill EA. Calcineurin acts in synergy with PMA to inactivate IκB/MAD3, an inhibitor of NF-κB. EMBO J 1994, 13, 861-870.
110. 2+-dependent signal transduction pathways. J Immunol 1995, 155, 4685-4691.
111. 111. Venkataraman L, Burakoff SJ, Sen R. FK506 inhibit antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 1995, 181, 1091-1099.
112. 112. Ruff VA, Leach KL. Direct demonstration of NFAT(p) dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFAT(p) polyclonal antibody. J Biol Chem 1995, 270, 22602-22607.
113. 113. Schulze-Osthoff K, Los M, Baeuerle PA. Redox signalling by transcription factors NF-κB and AP-1 in lymphocytes. Biochem Pharmac 1995, 50, 735-741.
114. 114. Vuillaume M. Reduced oxygen species, mutation, induction and cancer initiation. Mutat Res 1987, 186, 43-72.
115. 115. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991, 10, 2247-2258.
116. 116. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med 1992, 175, 1181-1194.
117. 117. Shibanuma M, Kuroki T, Nose K. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF-κB by tumor necrosis factor alpha in a mouse fibroblastic cell line, Balb/3T3. FEBS Lett 1994, 353, 62-66.
118. 118. Talley AK, Dewhurst S, Perry SW, Dollard SC, Gummuluru S, Fine SM, New D, Epstein LG, Gendelman HE, Gelbard HA. Tumor necrosis factor α-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Molec Cell Biol 1995, 15, 2359-2366.
119. 119. Sappey C, Boelaert JR, Legrandpoels S, Grady RW, Piette J. NF-κB transcription factor activation by hydrogen peroxide can be decreased by 2,3-dehydroxybenzoic acid and its ethyl ester derivative. Arch Biochem Biophys 1995, 321, 263-270.
120. 120. Meier B, Radeke HH, Selle S, Younes M, Sies H, Resch K, Habermehl GG. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumor necrosis factor-α. Biochem J 1989, 263, 539-545.
121. 121. Sappey C, Legrand-Poels S, Best-Belpomme M, Favier A, Rentier B, Piette J. Stimulation of glutathione peroxidase activity decreases HIV type 1 activation after oxidative stress. AIDS Res Hum Retrovir 1994, 10, 1451-1461.
122. 122. Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc Natl Acad Sci USA 1991, 88, 986-990.
123. 123. Mihm S, Ennen J, Pessara U, Kurth R, Droge W. Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives. AIDS 1991, 5, 497-503.
124. 124. Eugui EM, DeLustro B, Rouhafza S, Ilnicka M, Lee SW, Wilhelm R, Allison AC. Some antioxidants inhibit, in a co-ordinate fashion, the production of tumor necrosis factor-α, Il-1β, and Il-6 by human peripheral blood monuclear cells. Int Immunol 1994, 6, 409-442.
125. 125. Aillet F, Gourgerot-Pocidalo MA, Virelizier JL, Israël N. Appraisal of potential therapeutic index of antioxidants on the basis of their in vitro effects on HIV replication in monocytes and interleukin 2-induced lymphocyte proliferation. AIDS Res Hum Retrovir 1994, 10, 405-411.
126. 126. Israël N, Gougerot-Pocidalo M-A, Aillet F, Virelizier J-L. Redox status of cells influences constitutive or induced NF-κB translocation and HIV long terminal repeat activity in human T monocytic cell lines. J Immunol 1992, 149, 3386-3393.
127. 127. Hallwell B, Gutteridge JMC. The role of free radicals and catalytic metal ions in human diseases: an overview. Meth Enzym 1990, 186, 1-85.
128. 128. Das KC, Lewismolock Y, White CW. Thiol modulation of TNF-α and IL-1 induced MnSOD gene expression and activation of NF-κB. Molec Cell Biochem 1995, 148, 45-57.
129. 129. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Drige W, Lehnann V. HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J 1995, 14, 546-554.
130. 130. Suzuki YJ, Mizuno M, Packer L. Signal transduction for nuclear factor-κB activation. Proposed location of anti-oxidant-inhibitable step. J Immunol 1994, 153, 5008-5015.
131. 131. Menon SD, Qin S, Guy GR, Tan YH. Differential induction of nuclear NF-κB by protein phosphatase inhibitors in primary and transformed human cells. J Biol Chem 1993, 268, 26805-26812.
132. 132. Schmidt KN, Traenckner EB-M, Meier B, Baeuerle PA. Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-κB. J Biol Chem 1995, 270, 27136-27142.
133. 133. Schmidt HW, Walter U. NO at work. Cell 1994, 78, 919-925.
134. 134. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995, 76, 980-986.
135. 135. Peng H-B, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995, 270, 17050-17055.
136. 136. De Caterina R, Libby P, Peng H-B, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96, 60-68.
137. 137. Peng H-B, Libby P, Liao JK. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995, 270, 14214-14219.
138. 138. Geller DA, Nussler AK, Di-Silvio M, Lowenstein GJ, Shapiro RA, Wang SC, Simmons RL, Billiar TR. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitrous oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993, 90, 522-526.
139. 139. Hiscott J, Nguyen H, Lin R. Molecular mechanisms of interferon beta gene induction. Semin Virol 1995, 6, 161-173.
140. 140. Hiscott J, Petropoulos L, Lacoste J. Molecular interactions between HTLV-1 Tax protein and the NF-κB/IκB transcription complex. Virology 1995, 214, 3-11.
141. 141. Chen Z, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996, 84, 853-862.